@ARTICLE{10.3389/fimmu.2022.845217, AUTHOR={Liu, Jiayang and Meng, Zhefeng and Xu, Tongyang and Kuerban, Kudelaidi and Wang, Songna and Zhang, Xuyao and Fan, Jiajun and Ju, Dianwen and Tian, Wenzhi and Huang, Xuan and Huang, Xiting and Pan, Danjie and Chen, Huaning and Zhao, Weili and Ye, Li}, TITLE={A SIRPαFc Fusion Protein Conjugated With the Collagen-Binding Domain for Targeted Immunotherapy of Non-Small Cell Lung Cancer}, JOURNAL={Frontiers in Immunology}, VOLUME={13}, YEAR={2022}, URL={https://www.frontiersin.org/articles/10.3389/fimmu.2022.845217}, DOI={10.3389/fimmu.2022.845217}, ISSN={1664-3224}, ABSTRACT={The SIRPαFc fusion protein can block the immunosuppressive CD47-SIRPα signal between macrophages and tumor cells as a decoy receptor and has demonstrated its immunotherapeutic efficacy in various tumors. However, its clinical application was limited because of the potential hematologic toxicity. The heptapeptide “TKKTLRT” is a collagen-binding domain (CBD) which can bind collagen specifically. Herein, we aim to improve the tumor targeting of SIRPαFc and therefore avoid its unnecessary exposure to normal cells through synthesizing a TKKTLRT–SIRPαFc conjugate. Experiments at molecular and cellular levels indicate that the TKKTLRT–SIRPαFc conjugate-derived collagen-binding affinity and the introduction of CBD did not impact the CD47-binding affinity as well as its phagocytosis-promoting effect on NSCLC cells. In vivo distribution experiments showed that CBD–SIRPαFc accumulated in tumor tissue more effectively compared to unmodified SIRPαFc, probably due to the exposed collagen in the tumor vascular endothelium and stroma resulting from the abnormal vessel structure. On an A549 NSCLC nude mouse xenograft model, CBD–SIRPαFc presented more stable and effective antitumor efficacy than SIRPαFc, along with significantly increased CD11b+F4/80+ macrophages especially MHC II+ M1 macrophages within tumors. All of these results revealed that CBD brought a tumor-targeting ability to the SIRPαFc fusion protein, which contributed to the enhanced antitumor immune response. Altogether, the CBD–SIRPαFc conjugate may have the potential to be an effective tumor immunotherapy with improved antitumor efficacy but less non-tumor-targeted side effect.} }